Table
Table of Contents NU660 Psychopharmacology and Health promotion Neurotransmitter Chart (Unit 1) Antipsychotics Chart (Unit 2) Antidepressants, Anxiolytics, & Mood Stabilizers Chart (Unit 3, 4, 5) Substance Use Resources (Chart links) (Unit 6) Additional Resources List
|
Neurotransmitters Chart |
|||||||
|
|
Function (Excitatory or Inhibitory) |
Locations |
Receptors |
Effects of Deficient |
Effects of Surplus |
Agonist Drug |
Antagonist Drug |
|
Acetylcholine |
Excitatory- affects muscle movement, memory, arousal and helps maintain concentration. It plays as role in sustaining rapid eye movement while sleeping
|
Located in the PNS, CNS, |
Muscarinic and Nicotinic receptors |
Effects Alzheimer’s disease, myasthemia Gravis, memory loss |
Muscle contraction, muscle spams. Muscle weakness, Paralysis |
Bethanechol, pilocarpine, Cevimeline |
Oxyphenonium, Flavoxate, Oxybutynin, Trospium, atrophine |
|
Dopamine |
Both Inhibitory and excitatory. It is associated with the reward mechanism of the brain. Affects the inhabitation of prolactin, Disease affected include ADHD, RLS or Parkinson’s disease
|
Hypothalamus
CNS
Substantia Nigra
Ventral Tegmental Area |
D1, D2, C3, D4, D4, and D5. Hippocampal dentate |
Parkinson’s Disease, RLS, ADHD, Schizophrenia |
Schizophrenia and drug addiction, and mania. |
Pramipexole, Ropinirole, Pergolide Bromocriptine Rotigotine |
Ziprasidone, Droperidol Haloperidol Loxapine, Remoxipride Thiethylperazine,
|
|
Endorphins |
Inhibitory Released in response to stress of pain. It can improve mood and overall wellbeing. Can also be released during enjoyable activities
|
Pituitary gland
Hypothalamus
B-Endorphins- CNS |
Opioids receptors
Pre and Post Nerve Synaptic |
When released it can increase result in certain illnesses. Depression, anxiety, body aches, addiction. |
Depression, low testosterone, Decreases sex drive, Fatigue |
Opioids Methadone |
Naloxone |
|
GABA |
Inhibitory- Considered and Amino acid. As a neurotransmitter it sends messages from one neuron to another. Results in relaxation. As an inhibitory N/T it inhibits the transmission of other signals. |
Hippocampus
Thalamus
Basal Ganglia
Brainstem |
GABAc
Globus pallidus |
Low muscle tone, Hyperactive responses
Tremors,
Huntington disease
Anxiety
|
Eating disorders,
Sleeping disorder
Autism Intellectual disability |
Baclofen Zolpidem Sonata Pheno-barbital Placarbil |
Flumazenil Metrazol Pentetrazol Benzodiazepine SGS-742
|
|
Glutamate |
Excitatory Critical for thought memory and management of mood.
|
CNS Synaptic vesicles in nerve terminals |
AMPA Kainite Glia Brain Spine cord |
Huntington’s disease Mental exhaustion Difficulty with concentration |
Anxiety Stroke Autism Spectrum disorders Amyotrophic lateral sclerosis |
AMPA Quisqualis acid Topiramate Glutamic acid |
Haloperidol Memantine Ketamine Agmatine Amantadine |
|
Glycine |
Inhibitory functions an a anti-inflammatory antioxidant
|
Spinal cord, CNS |
Glyr Vertebrates. CNS Brainstem |
Hyperclycemia weakness Decreased muscle tone |
Hypotonia Hyperglycinemia Encephalopathy |
Atropine D- Alanine D-Serine L-Prolne L-serine Quisqualamine, Milacemide |
Brucine, thiocolchicoside Pitrazepin Picrotoxin Tutin |
|
Norepinephrine |
Excitatory- greatest release during the fight or flight response. Released at its lowest during sleep. It raises arousal, alertness, improves memory function. Can elevate blood pressure, HR and blood flow to GI tract
|
Locus Coeruleus Brain and spinal cord. |
Alpha 1 Alpha 2 Beta receptors |
Mood disorders Depression ADHD Changes in vital signs |
Hyperactivity Rapid HR Sweating HTN Irritability |
Phenylephrine Isoetharine Droxidopa Midodrine Pseudoephedrine |
Catarpress Risperdal Lopressor Sulpiride Nisoxetine |
|
Serotonin |
Inhibitory improves sexual desire, sleep, and bone health. Moves through the body and between brain cells to transmit messages.
|
CNS- Raphe Nuclei |
5-HT1 5-HT2 5-HT4 5-HT6 5-Ht7 |
Hyperactivity Digestive Phobia Post stress disorder |
Shivering Hyerreflexia AMS Autonomic hyperactivity and Autism. |
Frovatriptan Egotamine Eletriptan Zolmitriptan Lisuride Rizatriptan Zoloft |
Clozapine Risperidone Alosetron Ketanserin Ziprasidone Cyproheptadine Dolasetron |
Notes:
|
Antipsychotics |
||||||||||||||
|
First Generation |
|
|
|
|
|
|
|
Side Effects (L=Low, M=Moderate, H=High) |
|
|||||
|
Generic Name |
Trade Name |
Route(s) of Administration |
LAI option |
Starting Dose |
Half Life |
Indications (s/sx & diagnosis) |
MOA (neurotransmitter effects) |
EPS |
Hyperlipidemia |
T2DM |
Weight Gain |
Cognitive Issue |
Other SE |
Costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Second Generation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes:
|
Antidepressants, Anxiolytics & Mood Stabilizers |
||||||||||||||
|
Antidepressants |
|
|
|
|
|
|
|
Side Effects (L=Low, M=Moderate, H=High) |
|
|||||
|
Generic Name |
Trade Name |
Route(s) of Administration |
LAI option |
Starting Dose |
Half Life |
Indications (s/sx & diagnosis) |
MOA (neurotransmitter effects) |
EPS |
Hyperlipidemia |
T2DM |
Weight Gain |
Cognitive Issue |
Other SE |
Costs |
|
SSRIs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sertraline |
Zoloft |
Oral |
No LAI |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SNRIs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TCAs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MAOIs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Atypical |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Anxiolytics |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Benzodiazepines |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Barbiturates |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Mood Stabilizers |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PMHNP Journal for Clinical Practice
2
Last updated: 10/2020 nw
Notes:
Substance Use Chart
|
Generic Name |
Trade Name |
Route(s) of Administration |
LAI Option |
Starting Dose |
Half Life |
Indications (s/sx & diagnosis) |
MOA (neurotransmitter effects) |
EPS |
Hyperlipidemia |
T2DM |
Weight Gain |
Cognitive Issue |
Other SE |
Costs |
|
Substance Use |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Substance Use Resources
Commonly Used Drugs and Treatment Information Charts:
https://www.drugabuse.gov/sites/default/files/nida_commonlyuseddrugs_final_printready.pdf
Withdrawal Sx Chart